Superluminal Medicines
PrivateLast Round
Series B
Sep 3, 2026
Total Funding Raised
$213M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Superluminal Medicines is a biotechnology company that leverages generative biology, machine learning, and structural biology to accelerate the discovery and development of small molecule therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Superluminal Medicines Comparables
Compare Superluminal Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Deep Apple Therapeutics | 87% | |
| Genesis Therapeutics | 86% | |
| Charm Therapeutics | 85% |
Superluminal Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 3, 2026 | ||||
| Strategic | Aug 14, 2025 | ||||
| Series A | Sep 9, 2024 | ||||
| Seed | Aug 28, 2023 |
Superluminal Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B, Seed, Series A |
| Perceptive Advisors | Series B |
| Gaingels | Seed, Series B, Series A |
| Deep Track Capital | Series B |
| NVentures | Series B |
| Catalio Capital Management | Series B, Series A |
| BVF Partners L.P. | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 3, 2026
$60M round led by BVF Partners L.P.
- Aug 25, 2026
Grew 22% QoQ, from 49 to 60 employees.
Recent news
Latest coverage and updates
- is_developingSep 4, 2026
Superluminal Medicines, Inc. is developing drug discovery platform.
- is_developingSep 4, 2026
Superluminal Medicines, Inc. will develop MC4R agonist on Dec 31st '26.
- is_developingSep 4, 2026
Superluminal Medicines, Inc. is developing small molecule therapeutics targeting undisclosed GPCRs for cardiometabolic diseases and obesity.
- receives_financingSep 4, 2026
Superluminal Medicines, Inc. received financing of $60M in Series B on Sep 3rd '26.
Superluminal Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Superluminal Medicines's valuation, stock price, and market status.
Is Superluminal Medicines a public or private company?
Superluminal Medicines is a private company.
What is the current stock price of Superluminal Medicines?
Superluminal Medicines is a private company with no public stock price. No recent secondary market data is available.
How much is Superluminal Medicines worth (valuation)?
Valuation information for Superluminal Medicines is not publicly available.
Can I buy Superluminal Medicines stock?
Superluminal Medicines shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Superluminal Medicines's last funding round?
Superluminal Medicines's most recent funding round was Series A on September 9, 2024.
Who are the main investors in Superluminal Medicines?
Key investors in Superluminal Medicines include RA Capital Management.
Will Superluminal Medicines IPO soon?
No public IPO plans have been announced for Superluminal Medicines.
How can I track Superluminal Medicines secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Superluminal Medicines's secondary market activity and sign up for updates.